Related coverage linked through entity extraction aliases.
May 05, 2026
Neoadjuvant chemoimmunotherapy showed a 51.5% pathological complete response rate in 127 patients with resectable squamous cell lung cancer. Grade 3-4 treatment-related adverse events occurred in 11.8% of patients.
Apr 20, 2026
A pan-cancer study identified 56 local cellular programs and 13 spatial niches across 12 cancer types. Multiple niches were linked to prognosis, immunotherapy response, and macrophage spatial distribution.
Apr 05, 2026
Scientists are testing experimental cancer therapies including mRNA therapeutic vaccines, engineered EcN bacteria that deliver romidepsin in mice, and macrophage-targeted CAR T cells.
